The Cardio-Oncology Program at the University of Rochester Medical Center is a collaboration between URMC Cardiology and the James P. Wilmot Cancer Center. This unique, subspecialized program is led by Eugene Storozynsky, MD, PhD, a cardiologist trained and specialized in heart failure and transplantation.
The Cardiology-Oncology Program is the only one of its kind in Upstate New York. The goal is to identify patients with cancer who may be at an increased risk for chemotherapy-induced cardiotoxicity. High risk factors can include high blood pressure, heart rhythm abnormalities, silent coronary artery disease, heart valve complications, direct cardiotoxicity, and the development of the sequlae.
Through innovative imaging techniques such as strain echocardiography, cardiac MRI, angiography and associated endomyocardial biopsy, if necessary, we are able to identify these patients and modify their risk factors to minimize potential cardiotoxicity or to begin treatment on those who have already developed cardiotoxicity as a result of their chemotherapy.
Currently, there are nearly 25 chemotherapeutic agents with varying modes of actions that have been potentially associated with heart dysfunction. Additionally, the development of chemotherapy cardiotoxicity potentially limits the ability of oncologists to use chemotherapy agents known to eradicate cancer and limit the cancer's recurrence due to toxicity incurred with treatment.
Through the use of cardioprotective medications such as selective ACE-inhibitors, ARB's, beta blockers, and potentially aldosterone blockers, patients can keep receiving necessary chemotherapeutic agents while minimizing their risk for developing heart disease.
The Cardio-Oncology Program is located at the Paul N. Yu Heart Center adjacent to the James P. Wilmot Cancer Center.
Would you like to know more about the URMC Cardio-Oncology Program? Then please contact us at (585) 275-2475.